| 翻訳と辞書 |
Samatasvir
Samatasvir (IDX-719) is an experimental drug for the treatment of hepatitis C. It was originally developed by Idenix, and development has been continued by Merck & Co. following their acquisition of Idenix. Samatasvir has shown good results in Phase II trials.〔Vince B, Hill JM, Lawitz EJ, O'Riordan W, Webster LR, Gruener DM, Mofsen RS, Murillo A, Donovan E, Chen J, McCarville JF, Sullivan-Bólyai JZ, Mayers D, Zhou XJ. A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4. ''Journal of Hepatology''. 2014 May;60(5):920-7. doi: 10.1016/j.jhep.2014.01.003. PMID 24434503〕
Samatasvir is a highly potent and selective inhibitor of the hepatitis C virus NS5a replication complex.〔Bilello JP, Lallos LB, McCarville JF, La Colla M, Serra I, Chapron C, Gillum JM, Pierra C, Standring DN, Seifer M. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus. ''Antimicrobobial Agents and Chemotherapy''. 2014 Aug;58(8):4431-42. doi: 10.1128/AAC.02777-13. PMID 24867983〕 While it showed promising results when administered as a monotherapy, it is most likely that samatasvir would be marketed as a combination product with other anti-hepatitis drugs to increase efficacy, as with most other novel treatments for Hepatitis C currently under development. Trials of samatasvir in combination with other antiviral drugs such as simeprevir and ritonavir are also underway.〔(Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) )〕
==References==
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Samatasvir」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|